Learn More
OBJECTIVE To study the effect of fondaparinux, a new antithrombotic agent, as an anticoagulant during a 4-hour conventional hemodialysis session. materials and methods: Fondaparinux was administered as an anticoagulant to 16 chronic hemodialysis patients during a single 4-hour hemodialysis session at an intravenous bolus dose of 2.5 mg. Eight patients were(More)
BACKGROUND Several regimens using different doses of folic acid (FA) alone or supplemented with B-complex vitamins (BCVs) have been tested for their ability to reduce total homocysteine (tHcy) serum levels in hemodialysis (HD) patients. In the present study, we assessed the effect of two different doses comprising the simultaneous administration of(More)
Fifteen patients on hemodialysis, wearing acute dual lumen hemodialysis catheters (DLHCs) locked with a 4 ml heparin solution (HS) containing 7,500 IU of conventional heparin (3,750 IU/lumen), were studied. After the preexisting HS was aspirated and discarded, 10 ml of blood was withdrawn from each lumen in a syringe. Then, two 3 ml blood samples (A and B)(More)
We describe our experience with plasma exchange (PE) therapy in 13 patients with drug-induced toxic epidermal necrolysis (TEN), 4 of whom had malignant disorders. Skin lesions covered 17% to 100% of total body surface area and 1 to 4 mucous membranes were involved. None of the patients was hospitalized in a burn unit. The patients underwent from 2 to 5 PE(More)
The objective of this study was to assess changes of aspartate aminotransferase (AST [serum glutamic oxalacetic transaminase]) and alanine aminotransferase (ALT [serum glutamic pyruvic transaminase]) values after a hemodialysis (HD) session. Aspartate aminotransferase and ALT serum values were measured before and after a 4 h HD session in 37 stable patients(More)
The anticoagulant effects of two LMWHs, tinzaparin sodium and bemiparin sodium, were compared during two study dialysis (SD) sessions (SD1 with tinzaparin and SD2 with bemiparin) in ten chronic hemodialysis patients. Prior to SD1, patients had received 3,500 IU of tinzaparin in each dialysis session for two weeks. After SD1, they were switched to 3,500 IU(More)
In a review of 1057 patients who started receiving chronic haemodialysis treatment during the last decade in 16 renal units of Northern Greece only 25 patients (2.36%) were found to be older than 74 years at start of haemodialysis treatment. The most common cardiovascular problems in these elderly patients were angina pectoris in 9 and difficulties in(More)
Small vessel vasculitides, usually associated with positive antineutrophil cytoplasmic antibodies (ANCA(+)) can cause pulmonary-renal syndrome (PRS). Data from 22 patients, (19 males), aged 28-76 yrs (mean 55), with PRS were analyzed retrospectively. Renal function was estimated at presentation, 1 month after treatment initiation and at the end of follow-up(More)
Permanent pacemaker wires have been described as a cause of central vein stenosis. Furthermore, in hemodialysis (HD) patients with transvenous pacemakers, permanent vascular access (VA) created at the ipsilateral arm is not always successful. We report the use of tunneled double-lumen silicone HD catheters, as permanent VA in three HD patients wearing(More)